FAQ: Calidi Biotherapeutics Inc. Investor Webinar and Cancer Immunotherapy Pipeline

What is the purpose of Calidi Biotherapeutics’ investor webinar?

The webinar aims to spotlight Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including updates on CLD-201, CLD-400, and CLD-101, and feature a live Q&A session with Dr. Guy Travis Clifton, the new Chief Medical Officer.

When and where is the Calidi Biotherapeutics investor webinar taking place?

The live investor webinar is scheduled for April 24, 2025, at 4:15 p.m. ET. Details on how to access the webinar can be found in the full press release at https://ibn.fm/ppvW4.

Who is Dr. Guy Travis Clifton?

Dr. Guy Travis Clifton is the new Chief Medical Officer at Calidi Biotherapeutics, who will be featured in the webinar discussing the company’s cancer immunotherapy pipeline.

What are Calidi Biotherapeutics’ stem cell-based delivery platforms?

Calidi’s platforms use allogeneic stem cells to carry oncolytic viruses for treating various cancers, designed to enhance efficacy and patient safety by protecting, amplifying, and potentiating the viruses.

What is CLD-201?

CLD-201 is an FDA-cleared therapy by Calidi Biotherapeutics, advancing toward trials for solid tumors, part of the company’s stem cell-based delivery platforms for oncolytic virus therapies.

What other programs will be updated during the webinar?

Additional program updates will include CLD-400 for metastatic and lung cancer and CLD-101 for high-grade gliomas, showcasing Calidi’s broad approach to cancer immunotherapy.

How does Calidi Biotherapeutics’ approach to cancer treatment differ?

Calidi’s dual approach combines stem cell-based delivery platforms and enveloped virotherapies to target both localized and disseminated solid tumors, potentially treating or preventing metastatic disease.

Where is Calidi Biotherapeutics headquartered?

Calidi Biotherapeutics is headquartered in San Diego, California.

Where can I find more information about Calidi Biotherapeutics?

For more information, please visit www.calidibio.com.

What is InvestorWire’s role in this announcement?

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication and other corporate communications solutions, part of the Dynamic Brand Portfolio at IBN.